Moleculin Piotroski F Score

MBRX
 Stock
  

USD 1.49  0.01  0.67%   

This module uses fundamental data of Moleculin Biotech to approximate its Piotroski F score. Moleculin Biotech F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Moleculin Biotech CS. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Moleculin Biotech financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Additionally, see Moleculin Biotech Altman Z Score, Moleculin Biotech Correlation, Moleculin Biotech Valuation, as well as analyze Moleculin Biotech Alpha and Beta and Moleculin Biotech Hype Analysis.
  
Refresh
Moleculin Biotech Total Debt is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Debt of 63,000 in 2021. Debt Current is likely to rise to about 297.3 K in 2022, whereas Issuance Repayment of Debt Securities is likely to drop (281.7 K) in 2022. Moleculin Biotech Total Assets Per Share are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Assets Per Share of 2.94 in 2021. Net Current Assets as percentage of Total Assets is likely to rise to 88.37 in 2022, whereas Cash Flow Per Share is likely to drop (0.72)  in 2022.
At this time, it appears that Moleculin Biotech's Piotroski F Score is Very Weak. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
1.0
Piotroski F Score - Very Weak
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)DecreasingFocus
5
Asset Turnover GrowthN/AFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginNo ChangeFocus

Moleculin Biotech Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Moleculin Biotech is to make sure Moleculin is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Moleculin Biotech's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Moleculin Biotech's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares29 M26.9 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted29 M26.9 M
Significantly Up
Increasing
Slightly volatile
Total Assets90.7 M84.1 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities5.5 M5.1 M
Significantly Up
Increasing
Slightly volatile
Current Assets78.2 M72.5 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities3.3 M3.6 M
Significantly Down
Increasing
Slightly volatile
Total Debt64.7 K63 K
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

Moleculin Biotech F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Moleculin Biotech's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Moleculin Biotech in a much-optimized way.

About Moleculin Biotech Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

3.01

Share
Moleculin Biotech Book Value per Share is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Book Value per Share of 2.94 in 2021

Moleculin Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moleculin Biotech from analyzing Moleculin Biotech's financial statements. These drivers represent accounts that assess Moleculin Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moleculin Biotech's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(1.23 M)(913.54 K)(825.31 K)(1.15 M)(934.94 K)(1.01 M)
Average Assets20.42 M22.37 M27.2 M28.26 M91.53 M98.75 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings before Tax(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Average Equity17.8 M16.64 M17.83 M15.79 M83.37 M89.95 M
Enterprise Value30.58 M19.61 M26.74 M37.19 M(21.95 M)(22.53 M)
Free Cash Flow(7.35 M)(12.62 M)(17.25 M)(18.14 M)(18.97 M)(19.47 M)
Invested Capital(1.59 M)(2.58 M)58 K(51 K)(1.52 M)(1.56 M)
Invested Capital Average(1.37 M)(2.15 M)(4.8 M)(107.75 K)(1.3 M)(1.41 M)
Market Capitalization39.31 M28.21 M41.85 M49.79 M53.15 M51.11 M
Tangible Asset Value8.34 M8.44 M14.09 M17.88 M72.94 M78.7 M
Working Capital6.09 M4.1 M9.91 M14.28 M68.88 M74.31 M

About Moleculin Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech CS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech CS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moleculin Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamentals Comparison Now

   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moleculin Biotech Altman Z Score, Moleculin Biotech Correlation, Moleculin Biotech Valuation, as well as analyze Moleculin Biotech Alpha and Beta and Moleculin Biotech Hype Analysis. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.